Abstract
Corrigendum to Improvement in patient-reported outcomes of varicose veins following treatment with polidocanol endovenous microfoam. Phlebology. DOI: 10.1177/0268355516678512. First Published January 23, 2017
The following errors were corrected on the initial version of this paper:
All instances of VVSymQ® have been replaced with VVSymQ™. More details has been added to the conflicts in interests and funding statements, which now read:
Declaration of Conflicting Interests:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RM and DW are current or former employees of BTG International group companies, the manufacturer of PEM 1% [approved in the USA as Varithena® (polidocanol injectable foam), BTG International Ltd], and they performed this research during the course of their employment. BKL has received one-time consulting fees from a BTG International group company but was not compensated for participation in this manuscript.
Funding:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The VANISH-1 and VANISH-2 studies were sponsored by Provensis Ltd, a BTG International group company.
Subsequent versions of the article will be corrected.